Page 1911 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

1338 Index

Electronic medical record (EMR), 55 Endoscopic retrograde Evidence
Elevated liver enzymes, 856 cholangiopancreatography interpreting and applying, in critical care
Embolectomy, surgical, 331 (ERCP), 1163 medicine, 44–48
Embolization in acute pancreatitis, 1034 measures of association and quantifying
bronchial artery, 214–216, 215f Endoscopic therapy, 1012–1013, 1018, 1020 effect size, 46
in endovascular treatment, 220 Endoscopy, video capsule, 1021 observational studies, 45
foreign body, 226 Endothelin receptor modulators, 317 p values, confidence intervals, and power,
Emergency cricothyroidotomy and Endotracheal aspirates 46–47
tracheostomy, 400 qualitative cultures of, 525–526, 526f qualitative data and its role in critical
Emergency thoracotomy, 1157–1160 quantitative cultures of, 526 care research, 48
aortic rupture, 1159–1160, 1159f Endotracheal tube, changing, 392–393 randomized controlled trials, 45–46
blunt cardiac injury, 1159 Endovascular catheter directed surrogate outcomes measures in critical
cardiac tamponade, 1157–1158 thrombolysis, 216 care research, 46
diaphragmatic rupture, 1160 End-systolic V-P curve and contractility, 232 understanding diagnostic test, 47–48
esophageal disruption, 1160 Enhanced contractility, 309 translating, into practice, 33
indications, 1157 Enoxaparin, 301 Excellence, continuing compassion and, 4–5
lung contusion, 1158 Enteral nutrition Exemplary care
rib fractures, 1160 in burn patients, 1187–1188 critical care team in, 3
simple hemopneumothorax, 1160 sepsis and, 574 “do no harm” in, 3
Emerging antimicrobial resistance, in timing of, 136 hypotheses in, 2, 3f
enterobacteriaceae, 697–698, 697t Enteric infections, 616–617 interventions in, 2–3
Emphysematous pyelonephritis, 701 Enterobacteriaceae, emerging antimicrobial providing, 2–3
Empiric therapy in travelers, 716 resistance in, 697–698, 697t therapeutic goals in, 3
Empyema, 507, 583 Enterocolitis, necrotizing, 868 Exercise-induced anaphylaxis, 1271
Encephalitis, 665–676 Enteroscopy, deep, 1021 Exercise-induced hypoxemia, 518
bacterial, 674–675 Enteroviruses, nonpolio, 673 Exit site infection, 591
bunyaviridae, 673 Entrapment neuropathy and joint Extracorporeal CO 2 removal, 471–472
causes of, 666, 666t, 667–669t contractures, 109 Extracorporeal life support (ECLS) systems, 317
defined, 665–676 Envenomations, 1222–1223 Extracorporeal lung support, 470–482
flaviviridae, 671–672 EOLIA extracorporeal membrane oxygenation ECMO and 2007 influenza A (H1N1)
herpes simplex virus type I, 666, 669–671 (ECMO) trial, severe ARDS, 479–481
herpes viridae and, 666, 669–671 479, 480f ambulatory ECMO, 481
measles virus, 674 Epidemiology of antibiotic resistance, guidelines, 481
neonatal, 670 27, 27t for pulmonary emboli, 481
Nipah virus, 674 Epidural analgesia, 147 in trauma, 481, 481f
orthomyxoviridae, 673–674 Epidural hematomas, 1122 incremental approach to management of
paramyxoviridae, 674 Epilepsia partialis continua, 780 patients with severe hypoxemia,
picornaviridae, 672–673 Epstein-Barr virus (EBV), 671 471, 471f, 472f
postinfectious, 676 Equations, Cockroft-Gault, 544 initiation of ECMO, 473–476
protozoan, 675–676 Errors anticoagulation for, 474–475
rhabdoviridae, 673 cognitive, 36 cannulation, 473–474, 473f, 474f
togaviridae, 673 Type I, 47 complications related to, 476, 476f, 477t
Encephalopathy and elevated intracranial Type II, 47 parameters (Sv O 2 , Sa O 2 , hemoglobin,
pressure, acute liver failure and, Ertapenem, 546 platelets), 475
1024–1025, 1025t Erythema multiforme, 1289, 1290f supportive care on, 475–476
End-expiratory lung volume, 442–444, 443f Erythrocyte sedimentation rate, 1247 ventilator management during
Endobronchial infections, 1096 Erythroderma, 1293, 1293ft ECMO, 475
Endocarditis Erythropoietin in critically ill, 844 weaning off, 476, 476f
infective, 594–596, 594t, 596t Esmolol, 363 respiratory conditions requiring ECMO,
intravascular infections and, 593–600 Esophageal disruption, 1160 470, 471t
cavernous sinus thrombosis, 597 Esophagitis, 704–705 in specific indications
device-related, 598–599, 598t clinical presentation, 704 in ARDS and outcomes, 477, 477t, 478t
infection of venous structures, diagnosis of, 705 CESAR trial, 478
597–598, 597t microbiology, 704–705 ECMO outcomes in ARDS, 478
infective endocarditis, 594–596, therapy, 705 EOLIA ECMO trial, 479, 480f
594t, 596t Ethambutol, 641 meta-analysis of ECMO trials for ARDS,
mycotic aneurysms, 597 Ethanol, 1209–1210 478–479
pathogenesis of, 594 Ethics in withholding or withdrawing types of
native valve, 594 life sustaining therapies, candidates for ECMO for respiratory
Endocrine dysfunction, 566 121f, 123–124 failure, 472–473
Endocrine monitoring, in burn patients, 1188 Ethylenediamine tetraacetic acid extracorporeal CO removal, 471–472,
2
Endocrine response, 1046 (EDTA), 850 472t
Endocrine surgery special situations, Ethylene glycol, 1208 Extracorporeal membrane oxygenation
1076–1077 European Society of Intensive Care Medicine (ECMO), 470, 471, 472t
End-of-life care, interface between critical on size of intensive-care unit, 16 ambulatory, 481
care, palliative care and, 121 Euthyroid-sick syndrome, 987 anticoagulation for, 474–475

Index.indd 1338 23-01-2015 15:33:51